Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00336479 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C
A Phase 2 study, sponsored by Vertex Pharmaceuticals Incorporated.
- Completed
- Registry status
- Phase 2
- Development phase
- 263
- Enrollment target
NCT00336479: Completed Phase 2 study, sponsored by Vertex Pharmaceuticals Incorporated.
NCT00336479 is a Phase 2 study that has completed, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 263 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00336479, a Phase 2 study, has completed, sponsored by Vertex Pharmaceuticals Incorporated.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 263 participants
- Enrollment target
Study Summary
Study the effectiveness of telaprevir (VX-950) in combination with Pegylated Interferon Alfa 2a (Peg-IFN-alfa-2a) and Ribavirin (RBV) in reducing plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels
Primary Outcome
The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of detection was 10 international units per milliliter (IU/mL).
Interventions
- OTHER Placebo
- DRUG Ribavirin
- DRUG Telaprevir
- DRUG Pegylated Interferon Alfa 2a
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 263 participants |
| Start Date | 2006-06 |
| Est. Completion | 2008-02 |
| Phase | Phase 2 |
What the finished NCT00336479 record still lists
NCT00336479 is an interventional study that assigns participants to a tested intervention. The registered 263 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% higher).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00336479 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00336479 about?
NCT00336479 is a clinical study titled "Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C". Study the effectiveness of telaprevir (VX-950) in combination with Pegylated Interferon Alfa 2a (Peg-IFN-alfa-2a) and Ribavirin (RBV) in reducing plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels
What is the current status of trial NCT00336479?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 263 participants. The study started on 2006-06. Estimated completion is 2008-02.
What interventions are being tested in trial NCT00336479?
The interventions under investigation include: Placebo (OTHER), Ribavirin (DRUG), Telaprevir (DRUG), Pegylated Interferon Alfa 2a (DRUG).
Who is sponsoring clinical trial NCT00336479?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00336479's enrollment target sits among peer trials
263 210th of 2000 higher than 1,791 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04067336 · 263 participants · Phase 1
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
- NCT06234423 · 263 participants · Phase 1
A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
- NCT06724627 · 263 participants · NA
Application of the Belle.AI Dermatological Image Reference System for Patient Diagnosis in an Active Clinical Setting
- NCT04101669 · 264 participants · NA
RESET System Pivotal Trial (Rev F)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia